LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Medtronic PLC

Fermé

SecteurSoins de santé

87.41 0.59

Résumé

Variation du prix de l'action

24h

Actuel

Min

86.78

Max

87.41

Chiffres clés

By Trading Economics

Revenu

16M

1.3B

Ventes

-111M

8.3B

P/E

Moyenne du Secteur

23.197

51.198

BPA

1.62

Rendement du dividende

3.39

Marge bénéficiaire

15.605

Employés

95,000

EBITDA

-42M

2.4B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+10.07% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.39%

2.40%

Prochains Résultats

19 août 2025

Date du Prochain Dividende

11 juil. 2025

Date du Prochain Détachement de Dividende

27 juin 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-13B

107B

Ouverture précédente

86.82

Clôture précédente

87.41

Sentiment de l'Actualité

By Acuity

26%

74%

68 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Medtronic PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 mai 2025, 11:38 UTC

Résultats
Acquisitions, Fusions, Rachats

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

18 févr. 2025, 12:24 UTC

Résultats

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

21 mai 2025, 17:23 UTC

Actualités
Acquisitions, Fusions, Rachats

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21 mai 2025, 11:39 UTC

Actualités
Acquisitions, Fusions, Rachats

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21 mai 2025, 10:52 UTC

Résultats

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21 mai 2025, 10:51 UTC

Résultats

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21 mai 2025, 10:50 UTC

Résultats

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21 mai 2025, 10:49 UTC

Résultats

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

21 mai 2025, 10:49 UTC

Résultats

Medtronic Names Michael Carter Sr VP, President of Cranial, Spinal Technologies >MDT

21 mai 2025, 10:48 UTC

Résultats

Medtronic Names Skip Kiil Exec VP, President of Cardiovascular Portfolio >MDT

21 mai 2025, 10:48 UTC

Résultats

Medtronic: Sean Salmon, Exec VP and President of, Cardiovascular Portfolio Leaving >MDT

21 mai 2025, 10:47 UTC

Résultats

Medtronic Raises Quarterly Dividend to 71c From 70c >MDT

21 mai 2025, 10:45 UTC

Acquisitions, Fusions, Rachats

Medtronic: Preferred Path of Initial Public Offering, Subsequent Split-Off >MDT

21 mai 2025, 10:45 UTC

Résultats

Medtronic Reports Strong Finish To Its Fiscal Year With Its Fourth Quarter Financial Results; Announces Dividend Increase >MDT

21 mai 2025, 10:45 UTC

Résultats

Medtronic 4Q Net $1.06B >MDT

21 mai 2025, 10:45 UTC

Résultats

Medtronic 4Q Medical Surgical Portfolio Rev $2.21B >MDT

21 mai 2025, 10:45 UTC

Résultats

Medtronic 4Q Neuroscience Portfolio Rev $2.62B >MDT

21 mai 2025, 10:45 UTC

Résultats

Medtronic 4Q Diabetes Rev $728M >MDT

21 mai 2025, 10:45 UTC

Résultats

Medtronic 4Q Organic Revenue Up 5.4% >MDT

21 mai 2025, 10:45 UTC

Résultats

Medtronic 4Q Adj EPS $1.62 >MDT

21 mai 2025, 10:45 UTC

Résultats

Medtronic 4Q EPS 82c >MDT

21 mai 2025, 10:45 UTC

Résultats

Medtronic 4Q Cardiovascular Portfolio Rev $3.34B >MDT

21 mai 2025, 10:45 UTC

Résultats

Medtronic 4Q Sales $8.93B >MDT

21 mai 2025, 09:00 UTC

Actualités
Acquisitions, Fusions, Rachats

Medtronic to Separate Diabetes Business as Stand-Alone Company -- WSJ

21 mai 2025, 09:00 UTC

Acquisitions, Fusions, Rachats

Medtronic to Separate Diabetes Business, Sources Say -- WSJ

21 mai 2025, 09:00 UTC

Acquisitions, Fusions, Rachats

Medtronic's Separation of Diabetes Business to Finish Within 18 Months, Sources Say -- WSJ

21 mai 2025, 09:00 UTC

Acquisitions, Fusions, Rachats

Medtronic Diabetes Business Sales Totaled Nearly $2.5B in 2024 -- WSJ

27 févr. 2025, 10:30 UTC

Actualités

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 févr. 2025, 11:47 UTC

Résultats

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 févr. 2025, 11:46 UTC

Résultats

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

Comparaison

Variation de prix

Medtronic PLC prévision

Objectif de Prix

By TipRanks

10.07% hausse

Prévisions sur 12 Mois

Moyen 95.76 USD  10.07%

Haut 109 USD

Bas 87 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

21 ratings

11

Achat

10

Maintien

0

Vente

Score Technique

By Trading Central

83.26 / 84.875Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

68 / 380Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.